Brief: IMFINZI Plus IMJUDO Combined With lenvatinib And TACE Reduced The Risk Of Disease Progression Or Death By 30% In Embolization-Eligible Unresectable Liver Cancer In EMERALD-3 Phase Iii Trial
01/06/2026 13:06
BRIEF-IMFINZI Plus IMJUDO Combined With lenvatinib And TACE Reduced The Risk Of Disease Progression Or Death By 30% In Embolization-Eligible Unresectable Liver Cancer In EMERALD-3 Phase Iii Trial June 1 (Reuters) - AstraZeneca PLC AZN.L:
IMFINZI® (DURVALUMAB) PLUS IMJUDO® (TREMELIMUMAB-ACTL) COMBINED WITH LENVATINIB AND TACE REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 30% IN EMBOLIZATION-ELIGIBLE UNRESECTABLE LIVER CANCER IN EMERALD-3 PHASE III TRIAL
ASTRAZENECA - STRIDE WITH LENVA AND TACE SHOWS POSITIVE OVERALL SURVIVAL TREND VERSUS TACE ALONE
ASTRAZENECA - STRIDE WITH LENVA AND TACE SHOWS 13 MONTHS MEDIAN PFS VERSUS 9.8 MONTHS FOR TACE ALONE
Source text: ID:nBw9jWmFZa
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains